ACLX vs GILD

Arcellx retains its strong 10x growth potential, primarily driven by the anticipated FDA approval of CART-ddBCMA (anito-cel) by Q3 2026 for relapsed/refractory multiple myeloma. The critical partnership with Kite/Gilead continues to provide significant de-risking for development, manufacturing, and global commercialization, underpinning the company's competitive advantage. The ddCAR platform offer...

Gilead Sciences, with a current market capitalization of $182.03B, continues to be a robust biopharmaceutical leader, particularly in HIV and increasingly in oncology and cell therapy. Its strategic initiatives and robust pipeline (e.g., Trodelvy, Lenacapavir, cell therapies) position it for sustained incremental growth and market share gains in key therapeutic areas. However, the fundamental chal...